ALEXANDRIA, Va., Nov. 11 -- United States Patent no. 12,466,807, issued on Nov. 11, was assigned to Amplia Therapeutics Ltd. (Melbourne, Australia).
"Salt and crystal form of a FAK inhibitor" was invented by Christopher Burns (Melbourne, Australia) and John Lambert (Melbourne, Australia).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention is directed to the tartrate salt of a FAK inhibitor defined by formula (I) below, and the use of that inhibitor for treating a proliferative disease."
The patent was filed on March 27, 2020, under Application No. 17/598,187.
*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sec...